BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32559336)

  • 1. Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing.
    Chan SL; Liew HZW; Nguyen F; Thumboo J; Chow WC; Sung C
    Br J Clin Pharmacol; 2021 Mar; 87(3):886-894. PubMed ID: 32559336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.
    Samwald M; Xu H; Blagec K; Empey PE; Malone DC; Ahmed SM; Ryan P; Hofer S; Boyce RD
    PLoS One; 2016; 11(10):e0164972. PubMed ID: 27764192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact.
    van der Wouden CH; Bank PCD; Özokcu K; Swen JJ; Guchelaar HJ
    Genes (Basel); 2019 May; 10(6):. PubMed ID: 31146504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
    Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
    Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Many Patients Could Benefit From Pre-emptive Pharmacogenomic Testing and Decision Support? A Retrospective Study Based on Nationwide Austrian Claims Data.
    Kuch W; Rinner C; Gall W; Samwald M
    Stud Health Technol Inform; 2016; 223():253-8. PubMed ID: 27139411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
    Duarte JD; Dalton R; Elchynski AL; Smith DM; Cicali EJ; Lee JC; Duong BQ; Petry NJ; Aquilante CL; Beitelshees AL; Empey PE; Johnson JA; Obeng AO; Pasternak AL; Pratt VM; Ramsey LB; Tuteja S; Van Driest SL; Wiisanen K; Hicks JK; Cavallari LH;
    Genet Med; 2021 Dec; 23(12):2335-2341. PubMed ID: 34282303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
    Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND
    Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738
    [No Abstract]   [Full Text] [Related]  

  • 8. Pre-emptive pharmacogenomics implementation among polypharmacy patients 65 years old and older: a clinical pilot.
    Uber R; Hayduk VA; Pradhan A; Ward T; Flango A; Graham J; Wright EA
    Pharmacogenomics; 2023 Dec; 24(18):915-920. PubMed ID: 37965783
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PGx in psychiatry: Patients' knowledge, interest, and uncertainty management preferences in the context of pharmacogenomic testing.
    Kastrinos A; Campbell-Salome G; Shelton S; Peterson EB; Bylund CL
    Patient Educ Couns; 2021 Apr; 104(4):732-738. PubMed ID: 33414028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
    Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
    Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis.
    Virelli CR; Mohiuddin AG; Kennedy JL
    Transl Psychiatry; 2021 Oct; 11(1):509. PubMed ID: 34615849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
    Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
    JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care.
    Bank PCD; Swen JJ; Schaap RD; Klootwijk DB; Baak-Pablo R; Guchelaar HJ
    Eur J Hum Genet; 2019 Oct; 27(10):1532-1541. PubMed ID: 31227807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times.
    Bättig VAD; Roll SC; Hahn M
    Pharmacopsychiatry; 2020 Jul; 53(4):185-192. PubMed ID: 32045941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
    Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
    J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.
    Chenchula S; Atal S; Uppugunduri CRS
    Pharmacogenomics J; 2024 Mar; 24(2):9. PubMed ID: 38490995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implementation of preemptive pharmacogenomics in psychiatry.
    Skokou M; Karamperis K; Koufaki MI; Tsermpini EE; Pandi MT; Siamoglou S; Ferentinos P; Bartsakoulia M; Katsila T; Mitropoulou C; Patrinos GP;
    EBioMedicine; 2024 Mar; 101():105009. PubMed ID: 38364700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.
    Liko I; Lee YM; Stutzman DL; Blackmer AB; Deininger KM; Reynolds AM; Aquilante CL
    Pharmacogenomics; 2021 Apr; 22(5):263-274. PubMed ID: 33657875
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults.
    Chan SL; Ng HY; Sung C; Chan A; Winther MD; Brunham LR; Wee HL
    Pharmacogenomics J; 2019 Aug; 19(4):401-410. PubMed ID: 30250149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.